SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a Research Day on Wednesday, October 8, beginning at 12:15 p.m. EDT. A webcast of the presentations will be available live on the company website.
-- Strategic Company Overview, Jonathan Lim, M.D., President and Chief Executive Officer
-- Science and Technology Overview, Gregory Frost, Ph.D., Vice President and Chief Scientific Officer
-- Insulins -- Faster Acting, Regular and Analog, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development
-- Bisphosphonates -- Advantages of Subcutaneous Injection with rHuPH20, Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development
-- PEGPH20 -- A Targeted Therapy for Cancer Treatment, Patrick O'Connor, Ph.D., Vice President, Research
-- Chemophase -- Next Steps to Pivotal Trials, Richard C. Yocum, M.D., Vice President, Clinical Development and Medical Affairs
-- Commercial Opportunities -- The Value Proposition, Robert L. Little, Vice President and Chief Commercial Officer
Halozyme will conduct a live webcast of the presentations beginning at 12:15 p.m. EDT. To access the webcast over the internet, please go to the company website at http://www.halozyme.com. An archive of the presentation will be available on Halozyme's website shortly after the conclusion of the meeting.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products targeting the
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved